Re­gen­eron posts sec­ond look on Covid-19 an­ti­body cock­tail, boost­ing its case for EUA — but what about symp­tom al­le­vi­a­tion?

Re­gen­eron has re­vealed a sec­ond cut of da­ta on its Covid-19 an­ti­body cock­tail in the out­pa­tient set­ting — da­ta that it has sent straight to the FDA to boost its emer­gency use au­tho­riza­tion re­quest.

The new re­sults re­in­force what’s re­port­ed from the same tri­al last month, Re­gen­eron said, in­cor­po­rat­ing a to­tal of 799 non-hos­pi­tal­ized pa­tients with mild-to-mod­er­ate dis­ease. REGN-COV2 re­duced vi­ral load and pa­tient med­ical vis­its (any­thing rang­ing from hos­pi­tal­iza­tions, emer­gency room, ur­gent care vis­its to physi­cian of­fice and telemed­i­cine vis­its), meet­ing all the key end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER